Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years

Reese W. Randle, Courtney J. Balentine, Glen E. Leverson, Jeffrey A. Havlena, Rebecca S. Sippel, David F. Schneider, Susan C. Pitt

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background The impact of recent medical advances on disease presentation, extent of operation, and disease-specific survival for patients with medullary thyroid cancer is unclear. Methods We used the Surveillance, Epidemiology, and End Results registry to compare trends over 3 time periods, 1983–1992, 1993–2002, and 2003–2012. Results There were 2,940 patients diagnosed with medullary thyroid cancer between 1983 and 2012. The incidence of medullary thyroid cancer increased during this time period from 0.14 to 0.21 per 100,000 population, and mean age at diagnosis increased from 49.8 to 53.8 (P < .001). The proportion of tumors ≤1 cm also increased from 11.4% in 1983–1992, 19.6% in 1993–2002, to 25.1% in 2003–2012 (P < .001), but stage at diagnosis remained constant (P = .57). In addition, the proportion of patients undergoing a total thyroidectomy and lymph node dissection increased from 58.2% to 76.5% during the study period (P < .001). In the most recent time interval, 5-year, disease-specific survival improved from 86% to 89% in all patients (P < .001) but especially for patients with regional (82% to 91%, P = .003) and distant (40% to 51%, P = .02) disease. Conclusion These data demonstrate that the extent of operation is increasing for patients with medullary thyroid cancer. Disease-specific survival is also improving, primarily in patients with regional and distant disease.

Original languageEnglish (US)
Pages (from-to)137-146
Number of pages10
JournalSurgery (United States)
Volume161
Issue number1
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Survival
Therapeutics
Thyroidectomy
Medullary Thyroid cancer
Lymph Node Excision
Registries
Epidemiology
Incidence
Population
Neoplasms

ASJC Scopus subject areas

  • Surgery

Cite this

Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. / Randle, Reese W.; Balentine, Courtney J.; Leverson, Glen E.; Havlena, Jeffrey A.; Sippel, Rebecca S.; Schneider, David F.; Pitt, Susan C.

In: Surgery (United States), Vol. 161, No. 1, 01.01.2017, p. 137-146.

Research output: Contribution to journalArticle

Randle, Reese W. ; Balentine, Courtney J. ; Leverson, Glen E. ; Havlena, Jeffrey A. ; Sippel, Rebecca S. ; Schneider, David F. ; Pitt, Susan C. / Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. In: Surgery (United States). 2017 ; Vol. 161, No. 1. pp. 137-146.
@article{442f6f7d0bc34a3db267196b0fb79ac6,
title = "Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years",
abstract = "Background The impact of recent medical advances on disease presentation, extent of operation, and disease-specific survival for patients with medullary thyroid cancer is unclear. Methods We used the Surveillance, Epidemiology, and End Results registry to compare trends over 3 time periods, 1983–1992, 1993–2002, and 2003–2012. Results There were 2,940 patients diagnosed with medullary thyroid cancer between 1983 and 2012. The incidence of medullary thyroid cancer increased during this time period from 0.14 to 0.21 per 100,000 population, and mean age at diagnosis increased from 49.8 to 53.8 (P < .001). The proportion of tumors ≤1 cm also increased from 11.4{\%} in 1983–1992, 19.6{\%} in 1993–2002, to 25.1{\%} in 2003–2012 (P < .001), but stage at diagnosis remained constant (P = .57). In addition, the proportion of patients undergoing a total thyroidectomy and lymph node dissection increased from 58.2{\%} to 76.5{\%} during the study period (P < .001). In the most recent time interval, 5-year, disease-specific survival improved from 86{\%} to 89{\%} in all patients (P < .001) but especially for patients with regional (82{\%} to 91{\%}, P = .003) and distant (40{\%} to 51{\%}, P = .02) disease. Conclusion These data demonstrate that the extent of operation is increasing for patients with medullary thyroid cancer. Disease-specific survival is also improving, primarily in patients with regional and distant disease.",
author = "Randle, {Reese W.} and Balentine, {Courtney J.} and Leverson, {Glen E.} and Havlena, {Jeffrey A.} and Sippel, {Rebecca S.} and Schneider, {David F.} and Pitt, {Susan C.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.surg.2016.04.053",
language = "English (US)",
volume = "161",
pages = "137--146",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years

AU - Randle, Reese W.

AU - Balentine, Courtney J.

AU - Leverson, Glen E.

AU - Havlena, Jeffrey A.

AU - Sippel, Rebecca S.

AU - Schneider, David F.

AU - Pitt, Susan C.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background The impact of recent medical advances on disease presentation, extent of operation, and disease-specific survival for patients with medullary thyroid cancer is unclear. Methods We used the Surveillance, Epidemiology, and End Results registry to compare trends over 3 time periods, 1983–1992, 1993–2002, and 2003–2012. Results There were 2,940 patients diagnosed with medullary thyroid cancer between 1983 and 2012. The incidence of medullary thyroid cancer increased during this time period from 0.14 to 0.21 per 100,000 population, and mean age at diagnosis increased from 49.8 to 53.8 (P < .001). The proportion of tumors ≤1 cm also increased from 11.4% in 1983–1992, 19.6% in 1993–2002, to 25.1% in 2003–2012 (P < .001), but stage at diagnosis remained constant (P = .57). In addition, the proportion of patients undergoing a total thyroidectomy and lymph node dissection increased from 58.2% to 76.5% during the study period (P < .001). In the most recent time interval, 5-year, disease-specific survival improved from 86% to 89% in all patients (P < .001) but especially for patients with regional (82% to 91%, P = .003) and distant (40% to 51%, P = .02) disease. Conclusion These data demonstrate that the extent of operation is increasing for patients with medullary thyroid cancer. Disease-specific survival is also improving, primarily in patients with regional and distant disease.

AB - Background The impact of recent medical advances on disease presentation, extent of operation, and disease-specific survival for patients with medullary thyroid cancer is unclear. Methods We used the Surveillance, Epidemiology, and End Results registry to compare trends over 3 time periods, 1983–1992, 1993–2002, and 2003–2012. Results There were 2,940 patients diagnosed with medullary thyroid cancer between 1983 and 2012. The incidence of medullary thyroid cancer increased during this time period from 0.14 to 0.21 per 100,000 population, and mean age at diagnosis increased from 49.8 to 53.8 (P < .001). The proportion of tumors ≤1 cm also increased from 11.4% in 1983–1992, 19.6% in 1993–2002, to 25.1% in 2003–2012 (P < .001), but stage at diagnosis remained constant (P = .57). In addition, the proportion of patients undergoing a total thyroidectomy and lymph node dissection increased from 58.2% to 76.5% during the study period (P < .001). In the most recent time interval, 5-year, disease-specific survival improved from 86% to 89% in all patients (P < .001) but especially for patients with regional (82% to 91%, P = .003) and distant (40% to 51%, P = .02) disease. Conclusion These data demonstrate that the extent of operation is increasing for patients with medullary thyroid cancer. Disease-specific survival is also improving, primarily in patients with regional and distant disease.

UR - http://www.scopus.com/inward/record.url?scp=85006257536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006257536&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2016.04.053

DO - 10.1016/j.surg.2016.04.053

M3 - Article

C2 - 27842913

AN - SCOPUS:85006257536

VL - 161

SP - 137

EP - 146

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 1

ER -